Circulating Myocardial microRNA Signatures of Early Remodeling

Abstract

Cardiac remodeling is a pivotal process in the pathogenesis of heart failure, often commencing silently before overt clinical manifestations. Circulating myocardial microRNAs (miRNAs) have emerged as promising non-invasive biomarkers reflecting early molecular changes in the myocardium. This review synthesizes recent evidence on the role of circulating myocardial miRNA signatures in early cardiac remodeling, exploring their pathophysiological underpinnings, diagnostic utility, risk stratification, and therapeutic implications. Special attention is given to the integration of miRNA profiles into current clinical workflows, emerging technologies, and guideline recommendations, with a focus on translating benchside discoveries into bedside interventions for improved patient outcomes.

Introduction

Early cardiac remodeling, characterized by initial molecular and cellular alterations preceding structural and functional changes, is a critical determinant of eventual heart failure. The detection of remodeling at this incipient stage offers a unique opportunity for timely intervention. Circulating myocardial microRNAs (miRNAs), small non-coding RNA molecules regulating post-transcriptional gene expression, have revolutionized cardiovascular biomarker discovery. Their stability in circulation, specificity to myocardial tissue, and dynamic expression profiles in response to injury position them as potential sentinels of early pathological remodeling. This review aims to provide clinicians and healthcare professionals with a comprehensive, evidence-based understanding of the clinical relevance, diagnostic potential, and therapeutic implications of circulating myocardial miRNA signatures in early cardiac remodeling.

Epidemiology / Disease Burden

Heart failure remains a leading cause of morbidity and mortality worldwide, with a rising prevalence attributed to aging populations and improved survival from acute myocardial insults. Subclinical myocardial remodeling often precedes symptomatic heart failure by months or years. Epidemiological studies have demonstrated that up to 40% of patients with risk factors such as hypertension, diabetes, or ischemic heart disease develop evidence of early remodeling, detectable by advanced imaging or biomarker analysis, including miRNA signatures. The burden of disease is compounded by the lack of sensitive tools for early detection, resulting in delayed intervention and poor clinical outcomes.

Pathophysiology

The myocardial remodeling process is orchestrated by a complex interplay of molecular events encompassing cardiomyocyte hypertrophy, apoptosis, extracellular matrix remodeling, and inflammatory responses. MiRNAs such as miR-21, miR-133a, miR-1, and miR-208a have been implicated in the regulation of these remodeling pathways. For instance, miR-21 promotes fibrosis by targeting SPRY1 in cardiac fibroblasts, while miR-133a inhibits hypertrophy by repressing RhoA signaling. The dysregulation of these and other cardiac-enriched miRNAs is reflected in their altered plasma concentrations during the early phases of remodeling, offering mechanistic insights and biomarker potential.

Risk Factors

Traditional risk factors, including hypertension, coronary artery disease, diabetes mellitus, and valvular heart disease, predispose individuals to myocardial remodeling. Genetic predisposition, age, gender, and lifestyle factors such as obesity and physical inactivity further modulate risk. Recent research has shown that specific circulating miRNA profiles can stratify risk even among asymptomatic individuals, suggesting a role for miRNA-based screening in populations at elevated risk for cardiac remodeling and subsequent heart failure.

Clinical Features

Early myocardial remodeling is often clinically silent, lacking overt symptoms or signs. Subtle changes may include mild exercise intolerance, occasional palpitations, or transient dyspnea, but these are non-specific. The identification of circulating miRNA signatures associated with early remodeling offers a molecular window for detecting disease before the onset of traditional clinical features, thus bridging the gap between molecular pathology and clinical presentation.

Diagnosis

Current diagnostic modalities for early cardiac remodeling include echocardiography, cardiac MRI, and serum biomarkers such as natriuretic peptides. However, these tools may lack sensitivity in the detection of subclinical remodeling. Circulating myocardial miRNAs, detectable in peripheral blood, offer a non-invasive and highly specific diagnostic approach. Panels of miRNAs, particularly those enriched in the myocardium (e.g., miR-1, miR-133a, miR-208a, miR-499), have demonstrated robust discriminatory power for early remodeling in multiple studies. Integration of miRNA profiling with imaging and clinical risk scores can enhance diagnostic accuracy and facilitate timely intervention.

Treatment & Management

The management of early cardiac remodeling centers on addressing modifiable risk factors and instituting pharmacological therapies proven to attenuate remodeling processes, such as renin-angiotensin-aldosterone system inhibitors and beta-blockers. The use of circulating miRNA signatures enables personalized treatment strategies by identifying patients at greatest risk for progression and monitoring therapeutic response. Ongoing research into miRNA-targeted therapies, including antisense oligonucleotides and miRNA mimics, holds promise for direct modulation of remodeling pathways.

Recent Advances / Emerging Therapies

Advances in high-throughput sequencing and bioinformatics have enabled the identification of novel circulating miRNA signatures associated with specific remodeling phenotypes and outcomes. Therapeutic interventions targeting key miRNAs (e.g., antagomirs against miR-21 or miR-34a) have demonstrated efficacy in preclinical models, reducing fibrosis and improving cardiac function. Liquid biopsy approaches, integrating miRNA panels with other molecular markers, are under investigation for longitudinal monitoring and risk stratification. The translation of these findings into clinical practice is anticipated to revolutionize the management of early cardiac remodeling in the coming years.

Guideline Recommendations

While current heart failure and cardiac remodeling guidelines from major societies (ESC, ACC/AHA) do not yet include circulating miRNAs as standard diagnostic or prognostic markers, expert consensus supports their potential utility, particularly in high-risk populations and research settings. Ongoing clinical trials and validation studies are expected to inform future guideline updates, emphasizing the importance of integrating novel biomarkers, including miRNAs, with established clinical pathways for early detection and management of myocardial remodeling.

Conclusion

Circulating myocardial miRNA signatures represent a transformative advance in the detection, risk stratification, and management of early cardiac remodeling. Their integration into clinical practice offers the potential for earlier intervention, personalized therapy, and improved patient outcomes. Continued research, standardization, and incorporation into guideline-driven care are essential to realize the full promise of miRNA-based diagnostics and therapeutics in cardiovascular medicine.